Genomenon is a genomic intelligence company headquartered in Ann Arbor, Michigan. Founded in 2014 by Dr. Mark Kiel, it specializes in variant interpretation for rare diseases and cancer. Their Mastermind Genomic Intelligence Platform is a comprehensive source of published genomic evidence, aiding in diagnostics and therapeutics development. The platform was detailed in a research paper published in November 2020. Genomenon's leadership includes CEO Mike Klein, CSO & Co-founder Dr. Mark J. Kiel, and a team with extensive experience in genomics, software development, and sales. Their core values emphasize continuous learning, data-driven decisions, customer focus, humility, and perseverance.